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the writing of the report.
Abstract
Aims: Intraperitoneal	(IP)	insulin	administration	is	a	last‐resort	treatment	option	for	
selected	patients	with	 type	1	diabetes	mellitus	 (T1DM).	As	 the	 IP	 route	of	 insulin	
administration	mimics	the	physiology	more	closely	than	the	subcutaneous	(SC)	route,	
we	hypothesized	 that	 IP	 insulin	would	 result	 in	 less	oxidative	 stress	 (expressed	as	
systemic	level	of	free	sulphydryl	(R‐SH)	content)	compared	to	SC	insulin	in	subjects	
with T1DM.
Materials and methods: Prospective,	observational	case‐control	study.	Serum	thiol	
measurements	were	 performed	 at	 baseline	 and	 at	 26	weeks	 in	 age‐	 and	 gender‐
matched	patients	with	T1DM.	Serum‐free	thiols,	compounds	with	a	R‐SH	group	that	









demonstrate	 that	 the	 route	of	 insulin	administration,	 IP	or	SC,	does	not	 influence	
systemic	redox	status	in	patients	with	T1DM.
K E Y W O R D S
insulin,	intraperitoneal,	redox,	subcutaneous,	thiols,	type	1	diabetes	mellitus
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1  | INTRODUC TION
Currently,	 Continuous	 intraperitoneal	 insulin	 infusion	 (CIPII)	 is	
used	as	a	 last‐resort	 treatment	option	for	selected	patients	with	
type	1	diabetes	mellitus	(T1DM)	who	fail	to	reach	glycaemic	con‐
trol	 despite	 intensive	 subcutaneous	 (SC)	 insulin	 therapy.	 With	
CIPII,	 insulin	 is	 infused	 directly	 in	 the	 intraperitoneal	 (IP)	 space	
resulting in higher concentrations of insulin in the portal vein 
catchment	 area,	 higher	 hepatic	 insulin	 extraction	 and	 lower	 pe‐















Indeed,	 in	 the	animal	model,	delivering	 the	same	dose	of	 insu‐
lin	 IP	 resulted	 in	 lower	 hepatic	 oxidative	 stress	 and	 inflammation	
as	compared	to	continuous	SC	insulin	delivery.20	To	date,	however,	
there are no data on the effect of the route of insulin administra‐
tion	on	whole‐body	redox	status	in	humans.	We	hypothesized	that	
the	route	of	insulin	administration	affects	the	systemic	redox	status	
and	 that	 the	 IP	 route	may	have	a	beneficial	effect	 compared	with	




2  | MATERIAL S AND METHODS
2.1 | Study design, aims and outcomes
This	multicentre	study	was	investigator‐initiated	and	had	a	prospec‐





was	 to	 test	 the	 hypothesis	 that	 IP	 insulin	 therapy	would	 result	 in	
a	more	favourable	redox	status	compared	with	SC	 insulin	therapy.	
Serum‐free	 thiols,	 compounds	with	a	 free	sulphydryl	 (R‐SH)	group	
that	 are	 readily	 oxidized	 by	 reactive	 oxygen	 species,	 were	 used	












without	 interruptions	 of	 >30	 days,	 in	 order	 to	 avoid	 effects	 re‐
lated to initiating therapy. Inclusion criteria for cases were have 






daily	 subcutaneous	 injections	 (MDI)	 or	 continuous	 subcutane‐
ous	insulin	infusion	(CSII)),	for	the	past	4	years	without	interrup‐
tions	of	>30	days	and	a	HbA1c	at	 time	of	matching	≥	53	mmol/
mol.	 Exclusion	 criteria	 for	 the	 present	 study	 for	 both	 cases	 and	
controls	 included	 the	 following:	 impaired	 renal	 function	 (plasma	
creatinine	 ≥	 150	 µmol/L	 or	 Cockcroft‐Gault	 ≤	 50	 mL/min),	 car‐
diac	problems	(unstable	angina	or	myocardial	infarction	within	the	
previous	12	months	or	NYHA	class	III	or	IV	congestive	heart	fail‐
ure),	 cognitive	 impairment,	 current	or	past	psychiatric	 treatment	
for	schizophrenia,	cognitive	or	bipolar	disorder,	current	use	of	oral	
corticosteroids or suffering from a condition which necessitated 
corticosteroids	use	more	than	once	in	the	previous	12	months,	al‐
cohol	or	drug	abuse,	current	gravidity	or	plans	to	become	pregnant	







cal	 parameters	were	 collected.	During	 the	 fourth	 visit,	 5‐7	 days	
after	 the	 third	 visit,	 laboratory	 measurements	 were	 performed.	
Throughout	 the	 study	 period,	 insulin	 (human	 insulin	 of	 E.	 Coli	
origin,	 400	 IU/mL,	 trade	 name:	 Insuman	 Implantable®,	 Sanofi‐
Aventis)	was	administered	with	an	implantable	pump	for	IP	insulin	
users	 and	 patients	 using	CSII	 or	MDI	 continued	 their	 own	 insu‐
lin	regime	consisting	of	fast‐acting	insulin	analogues	and	for	MDI	
patients	also	long‐acting	insulin	analogues	or	NPH	insulin.	All	pa‐
tients received standard care. The implantable insulin pump used 
during this study and related procedures has been described in 
more detail previously.25,26
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2.4 | Measurements
Demographic	 and	 clinical	 parameters	 included	 the	 following:	 age,	
gender,	weight,	 length,	 blood	 pressure,	 smoking	 and	 alcohol	 habits,	
co‐morbidities,	medication	use,	year	of	diagnosis	of	diabetes,	presence	
of microvascular and macrovascular complications and previous insulin 
therapy	(kind	of	insulin,	dosage	and,	if	applicable,	the	number	of	daily	
injections	of	 the	previous	day).	Blood	pressure	was	measured	using	
a	 blood	 pressure	 monitor	 (M6	 comfort;	 OMRON	Healthcare)	 using	
the	highest	mean	of	4	measurements	(2	on	each	arm).	Patients	were	
instructed	to	visit	the	laboratory	in	a	fasting	state.	Laboratory	meas‐
urements	 included	 creatinine,	 c‐peptide,	 total	 cholesterol,	 aspartate	
aminotransferase	 (AST),	 alanine	 aminotransferase	 (ALT),	 y‐glutamyl	
transpeptidase	(gamma‐GT),	alkaline	phosphatase	and	urine	albumin/
creatinine	ratio	and	HbA1c.	HbA1c	was	measured	with	a	Primus	Ultra2	
system	 using	 high‐performance	 liquid	 chromatography	 (reference	
value	20‐42	mmol/mol).
Systemic	 redox	 status	 was	 assessed	 using	 measurements	 of	
thiols.	 Thiols	 are	 compounds	 with	 a	 free	 sulphydryl	 (R‐SH)	 moi‐
ety.	These	R‐SH	groups	are	readily	oxidized	by	ROS	and	other	re‐
active	 species.	 The	 circulating	 concentrations	 of	 total	 R‐SH	have	













phosphate	 buffer	 (pH	 7)	 was	 added	 to	 the	 samples.	 Following	
20	minutes	of	incubation	at	room	temperature,	absorption	was	read	
again.	The	concentration	of	R‐SH	in	the	samples	was	determined	by	
comparing	 the	 absorbance	 readings	 to	 a	 standard	 curve	 of	 L‐cys‐
teine	 (15‐1000	 µmol/L;	 Fluka	 Biochemika,	 Buchs,	 Switzerland)	 in	
0.1	mol/L	Tris	and	10	mmol/L	EDTA	(pH	8.2).










median	 (with	 interquartile	 range	 [IQR])	 for	 normally	 distributed	
and	 non‐normally	 distributed	 data,	 respectively.	 A	 significance	
level	 of	5%	 (two‐sided)	was	used.	Normality	was	examined	with	
Q‐Q	plots.	Differences	between	 the	 IP	 and	SC	groups	 averaged	
over the study period and in time were estimated using the general 
linear model.
A	regression	model	based	on	covariate	analysis	(ANCOVA)	was	
applied in order to adjust for possible baseline imbalances. In the 
model,	the	fixed	factors	CIPII	and	SC	insulin	therapy	were	used	as	




between both treatment modalities over the study period adjusted 
for baseline differences.







to	 identify	variables	 that	 are	 independently	 associated	with	R‐SH.	
Subsequently,	all	variables	that	associated	with	R‐SH	with	a	P‐value	
of	 <.1	 were	 included	 in	 the	 multivariable	 linear	 regression	 using	
backward	selection.	The	quality	of	 the	model	was	described	using	
the accuracy of the prediction by the adjusted R2 value. In order to 
avoid	collinearity,	only	the	coefficient	of	variation	(CV)	of	the	CGM	
measurements	was	used.	The	CV	measures	intraday	variation	in	glu‐
cose	patterns,	 is	 defined	 as	 the	SD	divided	by	 the	mean	of	 blood	
glucose values and is advocated to be the most optimal measure of 
glycaemic variability.30‐32







were screened and received information about the study; 190 
agreed	to	participate.	After	baseline	laboratory	measurements,	6	
patients	were	excluded	because	of	C‐peptide	concentrations	ex‐




were	 included	 in	 the	 present	 analyses.	 At	 baseline,	 39	 patients	
were	treated	with	IP	insulin	and	141	with	SC	insulin	(67	with	MDI	
and	74	CSII).	Mean	 age	of	 the	population	was	49.8	 (12.5)	 years,	
diabetes	duration	26.1	(12.3)	years	and	HbA1c	63.8	(10.5)	mmol/
mol	(see	Table	1).
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TA B L E  1  Baseline	characteristics
All (n = 180) IP (n = 39) SC (n = 141) MDI (n = 67) CSII (n = 74)
Clinical
Male	sex	(%) 67	(37) 14	(36) 53	(38) 23	(34) 30	(41)
Age	(years) 50	(12) 50	(12) 50	(13) 52	(12) 48	(12)
Current	smokers	(%) 77	(43) 20	(51) 57	(40) 27	(40) 30	(41)
Current	alcohol	use	(%) 58	(32) 10	(26) 48	(34) 24	(36) 24	(32)
BMI	(kg/m2) 26	(5) 25	(5) 27	(5) 26	(5) 26	(4)
Systolic	blood	pressure	(mm	Hg) 137	[123,	148] 136	[126,	152] 133	[123,	147] 134	[123,	150] 133	[123,	145]
Diabetes	duration	(years) 26	[17,	35] 29	[22,	36] 23	[16,	35] 22	[13,	35] 25	[17,	35]
Retinopathy	present	(%) 62	(34) 17	(44) 45	(32) 17	(25) 28	(38)
Neuropathy	present	(%) 50	(28) 20	(51.3) 30	(21)* 16	(24)	* 14	(19)	*
Nephropathy	present	(%) 5	(2.8) 2	(5.1) 3	(2.1) 1	(2) 2	(3)
Macrovascular	complication	present	(%) 26	(14) 7	(18) 19	(14) 10	(15) 9	(12)
Basal	insulin	dose	(IU/d/kg) 0.4	[0.2,	0.4] 0.4	[0.3,	0.7] 0.3	[0.2,	0.4]* 0.3	[0.2,	0.4]* 0.3	[0.2,	0.4]*
Bolus	insulin	dose	(IU/d/kg) 0.3	[0.2,	0.4] 0.2	[0.1,	0.3] 0.3	[0.2,	0.4]* 0.4	[0.3,	0.5]* 0.2	[0.2,	0.3]	**
Total	insulin	dose	(IU/d/kg) 0.7	[0.5,	0.8] 0.7	[0.5,	0.9] 0.6	[0.5,	0.8] 0.7	[0.5,	0.8] 0.6	[0.4,	0.7]* 
Biochemical
HbA1c	(mmol/mol) 63.8	(10.5) 66.9	(14.4) 62.8	(8.9) 62.3	(9.1) 63.4	(8.8)
Fasting	glucose	(mmol/L)* 8.6	(3.7) 8.4	(3.8) 8.7	(3.7) 8.5	(3.8) 8.8	(3.7)
C‐peptide 0.01	[0.01,	0.01] 0.01	[0.01,	0.01] 0.01	[0.01,	
0.02]
0.01	[0.01,	0.02] 0.01	[0.01,	0.01]
C‐reactive	protein 1.0	[1.0,	3.0] 2.0	[1.0,	5.8] 1.0	[1.0,	3.0] 1.0	[1.0,	3.3] 1.0	[1.0,	2.0]
Creatinine	(μmol/L) 69.4	(13.0) 70.0	(12.3) 69.4	(13.2) 69.3	(14.2) 69.4	(12.4)
Albumin	(g/L) 41.0	(5.7) 41.8	(6.5) 40.9	(5.5) 40.8	(5.4) 41.0	(5.6)
Alkaline	phosphatase	(U/L) 73.2	(20.5) 78.1	(18.6) 71.9	(20.8) 72.4	(19.7) 71.4	(21.9)
Gamma‐GT	(U/L) 19.0	[14.0,	27.8] 22.0	[14.0,	36.0] 19.0	[14.0,	27.0] 17.0	[13.0,	26.0] 21.0	[14.0,	17.8]
AST	(U/L) 23.0	[19.0,	27.0] 24.0	[20.0,	25.0] 23.0	[19.0,	27.0] 23.0	[20.0,	27.0] 23.0	[18.0,	28.3]
ALT	(U/L) 18.0	[14.0,	24.8] 20.0	[15.0,	24.0] 18.0	[14.0,	25.0] 18.0	[15.0,	25.0] 18.0	[13.0,	25.0]
Total	cholesterol	(mmol/L) 4.8	(0.9) 4.9	(1.0) 4.8	(0.8) 4.8	(0.8) 4.7	(0.8)
HDL‐cholesterol 1.8	(0.5) 1.7	(0.5) 1.8	(0.5) 1.8	(0.6) 1.7	(0.4)
LDL‐cholesterol 2.6	(0.8) 2.8	(0.9) 2.6	(0.8) 2.5	(0.8) 2.6	(0.7)
Triglycerides 0.8	[0.6,	1.0] 1.0	[0.7,	1.6] 0.8	[0.6,	1.1] 0.8	[0.7,	1.2] 0.8	[0.6,	1.0]
Microalbuminuria:creatinine ratio 0.9	[0.5,	1.7] 1.2	[0.5,	1.8] 0.8	[0.4,	1.4] 1.0	[0.5,	2.1] 0.8	[0.4,	1.4]
CGM	measurements
Hypoglycaemia	(%) 5.4	[1.2,	10.4] 2.4	[0.0,	6.7] 6.1	[1.6,	10.9] 9.7	[3.1,	13.9]	* 3.6	[1.0,	7.2]	**
Euglycaemia	(%) 52.8	[41.6,	62.1] 49.0	[30.9,	59.1] 54.0	[43.7,	62.3] 55.7	[43.0,	61.9] 51.6	[45.0,	62.5]




Mean 9.6	(2.0) 10.6	(2.4) 9.4	(1.8)	* 9.0	(1.8)	* 9.8	(1.6)	**
SD 3.9	(0.9) 3.9	(1.1) 3.8	(0.9) 4.0	(1.0) 3.8	(0.8)
CV 41.0	(9.0) 37.2	(8.4) 41.9	(8.8)	* 44.8	(9.6)	* 39.3	(7.4)	**
MAGE 7.8	(2.5) 7.7	(2.6) 7.9	(2.5) 7.9	(2.7) 7.8	(3.2)
MODD 4.1	(1.3) 3.9	(1.1) 4.1	(1.4) 4.1	(1.7) 4.1	(1.1)
Note: Data	are	presented	as	n	(%),	mean	(SD)	or	median	[IQR].	P‐values	are	based	on	appropriate	parametric	and	nonparametric	tests.	Retinopathy,	

































Beta P‐value Part correlation
Gender	(male	=	1) −0.075 .324
Age	(years) −0.358 <.001 −0.313 <.001 −.302
Current	smokers	(yes	=	1) 0.017 .819
Current	alcohol	use	(%) 0.094 .219



































line and at the end of the study were higher among T1DM patients 
treated	with	 IP	 insulin,	 this	was	not	significantly	different	as	com‐
pared	to	the	group	of	patients	treated	with	SC	insulin.
In	the	only	previous	study	(by	Dal	et	al)	that	investigated	the	in‐
fluence	of	 the	 route	of	 insulin	administration	on	 the	 redox	 status,	
an	identical	dose	of	insulin	was	administered	for	4	weeks	via	the	IP	
and	SC	route	to	STZ‐induced	diabetic	rodents.20 This resulted in less 
liver	and	global	inflammation,	as	measured	by	alpha‐2‐macroglobulin	
with	IP	insulin.20	In	addition,	they	observed	increases	in	IGF‐1	and	a	
decrease in blood glucose concentration.
The	 previous	 observations	 that	 IP	 insulin	 administration	 in	
human	T1DM	patients	results	 in	 lower	Hba1c,	 less	glycaemic	vari‐
ability	and	higher	IGF‐1	levels	as	compared	to	SC	insulin	treatment	
19,24,33	 led	 to	 the	 hypothesis	 tested	 in	 this	 study	 that	 IP	 insulin	
therapy	per	se	would	have	beneficial	effect	on	the	redox	status	as	
compared	to	SC	insulin.	However,	no	differences	in	redox	status	be‐
tween the different routes of insulin administration were observed 
in the current study.








Obviously,	 differences	 in	 treatment	 duration,	 species	 and	 the	
parameters	of	oxidative	stress	used	could	also	account	for	the	dif‐
ferent findings of this study as compared to Dal et al In the cur‐








As	 expected,	 obesity	 and	 ageing	 were	 inversely	 associated	
with	 increased	oxidative	stress.34	To	 the	best	of	our	knowledge,	
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association	of	R‐SH	and	albumin	was	more	or	less	expected.	Ates	
et al were the first to investigate levels of free thiols in persons 
with	T1DM.	 In	their	study,	among	38	subjects	significantly	more	
thiol	 oxidation	 among	patients	with	T1DM	was	 present	 as	 com‐
pared to healthy controls.36	In	addition,	a	correlation	between	R‐
SH	with	glucose,	HbA1c	and	inflammatory	markers	was	observed.	




in	 size	 and	 characteristics	 of	 the	 study	 population	may	 be	 held	






determinant of thiol concentrations than glycaemia.
Strengths	of	the	present	study	include	the	inclusion	of	patients	
who have been using their current route of therapy for at least 
4	years,	thus	creating	a	stable	situation,	and	measurements	made	on	
two	points	in	time.	During	the	study	period,	there	was	an	increase	





were involved here. Other limitations should be mentioned. Major 
limitation	of	the	present	study	is	the	nonrandomized	design.	Ideally,	
R‐SH	measurements	should	be	performed	prior	and	after	initiation	
of	 IP	 insulin	 therapy	 to	 compare	 the	 changes	 in	R‐SH	 status	 from	
baseline	 (with	 SC	 insulin	 therapy).	 However,	 the	 global	 shortage	
of implantable insulin pumps precludes such a study design. Taken 







plasma	antioxidant	 species	 such	 as	 ascorbate,	 uric	 acid	 and	 small‐
molecular‐weight	 thiols	 and	markers	 of	 inflammation	 (due	 to	 cost	
constraints)	should	be	mentioned.
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